Cannabis Testing Company Sales Jump 438%

Analysis originally distributed on March 21, 2018 By: Michael Vodicka of Cannabis Stock Trades

Cannabis testing services is a high-growth cannabis sub-industry.

According to data from cannabis industry media company, High Times, the cannabis lab testing industry was valued at $866MM in 2016.

With more countries legalizing cannabis, demand for testing is expected to soar, with the cannabis testing industry expected to grow to $1.4 billion by 2021.

Today - I am going to reveal a little-known cannabis company cashing in big time from this high-growth sub-industry.

  • Sales were up 438% in 12 months.
  • It continues to expand in high-growth California.
  • Shares are trading almost 50% below the 52-week high.

Evio Labs (OTC:EVIO) is a promising young cannabis company headquartered in Oregon with a market cap of $18MM.

I see a lot of growth potential for Evio.

This company provides mission-critical testing services to cannabis growers.

It's important to understand the entire cannabis industry - particularity growers - are subjected to a rigorous compliance.

Like analysis from Michael Vodicka of Cannabis Stock Trades?

To get the latest analysis as soon as it is released, please subscribe to our free weekly newsletter

Cannabis Stock Trades provides investors reliable information on the cannabis industry and the small group of hidden companies that are cashing in on this explosive trend.

Cannabis growers are required to hit certain regulatory targets and can then be required to report those results to regulators.

For example, cannabis growers and retailers can be required to self-test and report to regulators to ensure public safety.

On the consumer side of the business, cannabis growers have a strong financial incentive for quality and consistency. That is good for sales and branding.

Evio is a key partner that helps cannabis growers hit these goals - offering a wide range of cannabis testing services.

Here a few examples of its chemical testing services.

Cannabinoid Analysis:

Not only are producers and consumers concerned with product purity and safety, but there is also a need to properly characterize Cannabis potency.

Residual Solvent Analysis:

We can assist in the detection of many residual solvents used in Cannabis extract production including butane, propane, hexane, acetone, ethanol, and more.

Evio Labs

The company operates nationally but is heavily focused on the high-growth west coast cannabis industry.

It currently has locations in Oregon, California, Florida, Colorado and Massachusetts.

Evio Labs

2017 Sales Surge 438% from 2016

This company is thriving. I'm impressed with sales growth.

In 2017, Evio delivered some of the best sales growth I've ever seen in the cannabis industry.

Here are a few key stats directly from the press release.

  • EVIO's Fiscal Year 2017 revenue was $3,021,030, an increase of 438 percent on a year over year basis. A majority of the growth came from increased testing revenue, which was up 782 percent, while consulting services increased by 27 percent.
  • Fourth quarter revenues were $742,633, an increase of 339 percent over the same period in 2016.
  • Gross profit margin increased from 6 percent in 2016 to 19 percent in Fiscal Year 2017.

Looking forward I am expecting plenty more growth. Evio continues to add new locations with an emphasis on high-growth markets in Oregon and California.

For example, on December 11 of 2017 it has signed a non-binding letter of intent to acquire 60% of C3 Labs, LLC.

"Located in Berkeley, CA, C3 Labs has been serving the cannabis industry since 2015. a C3 Labs has been issued a Cannabis Research and Development business license by the City of Berkeley that permits them to provide cannabis scientific research, product design, development and testing. C3 Labs was one of the nation's first, true, cannabis-focused contract research organization (CRO), with both field services and a state of the art research center in beautiful Berkeley, California."

With California legalizing recreational cannabis in January I am expecting this new facility and other to drive another year or big-time sales growth.

Shares Were up Big in 2017 But are Down Almost 50% in 2018

EVIO rallied with the broader cannabis sector in late 2017. Since then shares have been weak, down almost 50% in 2018.

Evio Labs

I don't view this weakness a signal Evio isn't doing well. I see it a profit-taking in the short run. In the long run, I see it as a chance to be aggressive on a pullback.

Looking forward, I am expecting to see another year of strong sales growth and that should support shares on the chart.

Speaking of shares - this stock is traded on US OTC markets - otherwise known as a "penny stock."

This ticker looks plenty liquid. I see average daily trading volume of 130,000.

Risks to Consider

US cannabis companies are still struggling with high levels of legal risk. Although the industry is still growing a ton, the legal uncertainty is slowing progress and keeping billions in fresh capital out of the industry and sector.

Action to Take

Evio is an early industry leader in cannabis testing solutions. The company is a direct play on the US cannabis industry - particularly the high-growth west coast market. This is a tiny stock so I am expecting volatility. But in the long run, I am expecting big-time sales growth and bullish movement on the chart.


Michael Vodicka
Editor, Cannabis Stock Trades

The information contained in this post is for informational and educational purposes only. The trading ideas and stock selections represented on the Cannabis Stock Trades website are not tailored to your individual investment needs. Readers and members are advised to consult with their financial advisor before entering into any trade. Cannabis stocks carry a certain level of risk and we accept no responsibility for any potential losses. All trades, patterns, charts, systems, etc. discussed are for illustrative purposes only and not to be construed as specific advisory recommendations. All ideas and material presented are entirely those of the author and do not necessarily reflect those of the publisher.